Recombinant Cynomolgus/Rhesus Siglec-3/CD33 His Protein, CF

Recombinant Cynomolgus/Rhesus Siglec-3/CD33 His Protein, CF Summary

Product Specifications

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: Siglec-3/CD33

Sialic acid-binding Ig-like lectin 3 (Siglec-3), also known myeloid cell surface antigen CD33 (CD33), is a I-type (Ig-type) lectin belonging to the sialoadhesin subclass of the immunoglobulin superfamily (1). Siglecs are characterized by an N-terminal Ig-like V-type domain, which mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains in the extracellular domain (ECD). Fourteen human and nine mouse Siglecs have been characterized and are divided into 2 families: CD33 related and evolutionarily conserved (1-3). Mature Siglec-3 consists of an ECD with one Ig-like V-type domain and one Ig-like C2 domain, a single transmembrane and a cytoplasmic tail containing two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (3). Within the ECD, cynomolgus/rhesus Siglec-3 shares 89% amino acid sequence identity with human Siglec-3. An isoform of Siglec-3 lacking the N-terminal V-type domain, generated by alternative splicing, has been identified in humans (4). Siglec-3 is a disulfide-linked homodimer expressed on neutrophils, monocytes, macrophages and dendritic cells (2). Each Siglec family member has a distinct preference for binding the various types of sialylated glycans found on the surface of mammalian cells and they most likely evolved to regulate host immune responses via the recognition of self-glycans (5). Siglec-3 may be implicated in the regulation of both the innate but also the adaptive immunity and human Siglec-3 continues to be a therapeutic target for the treatment of acute myeloid leukemia and is a high potential risk factor for Alzheimer's (6). Siglec-3's ligands have yet to be classified, however terminal epitope preferences are conserved between Siglec-3 and Siglec-9 when binding to glycans (7). R&D Systems in-house testing indicates that Siglec-3 binds to LGALS3BP, consistent with the demonstrated functional interactions between other members of these protein families (8).

Manufacturing Specifications

Related Research Areas

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Common Macrophage Markers
• Dendritic Cell Activation
• Dendritic Cell ITIM/ITAM Immunoreceptors
• Ig-type Lectins
• ITIM/ITAM Immunoreceptors and Related Molecules
• Microglia Activation Markers
• Monocyte Markers
• Myeloid Lineage Markers
• Myeloid-derived Suppressor Cells (MDSC)
• Search Immune Checkpoint Targets